Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.38 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18235344 | 0.86 | KDM4E (0.31) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL21241061 | 0.82 | CYP1A2 (0.34) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL21720725 | 0.80 | SMN1; SMN2 (0.31) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL21720680 | 0.80 | KDM4E (0.31) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL21720685 | 0.80 | KDM4E (0.31) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL11295079 | 0.76 | — | — | |
| SCHEMBL10110590 | 0.76 | HSPA5 (0.34) | — | |
| SCHEMBL21720679 | 0.76 | LMNA (0.42) | ALDH1A1ALOX15CA2CA1LMNA | |
| SCHEMBL22792585 | 0.76 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2ALOX15KDM4ECYP1A2 | |
| SCHEMBL9944597 | 0.74 | GABRA1 (0.30) | CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | ZHEJIANG UNIVERSITY (CN) | 2024-07-11 | — | — | US | disclosed |
| CN-117881658-A | Two-step synthesis of pyrrole compounds from furan compounds | 切弗朗菲利浦化学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2022-06-09 | — | — | US | disclosed |
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-9433622-B2 | Pyrimidine compounds useful in the treatment of diseases mediated by IKKE and/or TBK1 mechanisms | CASE WESTERN RESERVE UNIVERSITY (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | DOMAINEX LIMITED (GB) | 2016-01-07 | — | — | US | disclosed |
| US-20080207864-A1 | Organosilanes, Process For Production of the Same, and Use Thereof | SHARP KABUSHIKI KAISHA (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2008-06-26 | — | — | US | disclosed |
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | SMITHKLINE BEECHAM CORPORATION | 2008-04-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2008-01-03 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282588-B2 | Azaindole inhibitors of aurora kinases | SMITHKLINE BEECHAM (US) | 2007-10-16 | — | — | US | disclosed |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | GLAXOSMITHKLINE LLC | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090830-A1 | Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists | EDNRB, TBXA2R, BDKRB1 | ALDH1A1 4470/4885SMN1; SMN2 4159/4885ALOX15 755/4885 |
| US-20240025924-A1 | HETEROCYCLE SUBSTITUTED KETONE DERIVATIVE, AND COMPOSITION AND MEDICINAL USE THEREOF | BCKDK, CYP11B2, HSD17B7 | ALDH1A1 348/4885SMN1; SMN2 2421/4885ALOX15 1612/4885 |
| US-20160289212-A1 | HEPATITIS B ANTIVIRAL AGENTS | ZC3HAV1, HAVCR2, SLC10A1 | ALDH1A1 3565/4885SMN1; SMN2 4742/4885ALOX15 2947/4885 |
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | ALDH1A1 2905/4885SMN1; SMN2 3951/4885ALOX15 1395/4885 |
| US-20160000784-A1 | PYRIMIDINE COMPOUNDS USEFUL IN THE TREATMENT OF DISEASES MEDIATED BY IKKE AND/OR TBK1 MECHANISMS | TBK1, TBKBP1, TYMS | ALDH1A1 4351/4885SMN1; SMN2 1899/4885ALOX15 4190/4885 |
| US-20070149561-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | ALDH1A1 1793/4885SMN1; SMN2 3558/4885ALOX15 4699/4885 |
| US-20080081808-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | ALDH1A1 1793/4885SMN1; SMN2 3558/4885ALOX15 4699/4885 |
| US-20230203060-A1 | FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | KRAS, NRAS, TP53 | ALDH1A1 3223/4885SMN1; SMN2 3268/4885ALOX15 3479/4885 |
| US-20080153843-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS | SULT2A1, STS, SULT1A1 | ALDH1A1 1535/4885SMN1; SMN2 45/4885ALOX15 2400/4885 |
| US-20220177462-A1 | SUBSTITUTED HETEROCYCLIC AMIDE COMPOUND AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | ALDH1A1 4437/4885SMN1; SMN2 3637/4885ALOX15 1739/4885 |
| US-20240228487-A1 | FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND APPLICATION THEREOF | TRPM2, TRPM8, TRPM7 | ALDH1A1 2555/4885SMN1; SMN2 1420/4885ALOX15 2358/4885 |
| US-20080004308-A1 | AZAINDOLE INHIBITORS OF AURORA KINASES | AURKA, AURKC, AURKB | ALDH1A1 1793/4885SMN1; SMN2 3558/4885ALOX15 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.